Diabetes mellitus in the outcome of acute and chronic pancreatitis. The current state of the problem
AbstractAmong patients with diabetes mellitus, a separate group consists of persons in whom a disorder of carbohydrate metabolism occurs secondary to the disease or surgical intervention on the pancreas. In 2019 the World Health Organization (WHO) approved the name «Diabetes of the Exocrine Pancreas» (DEP). Diabetes mellitus in the outcome of pancreatitis – post-pancreatic diabetes mellitus (PPDM) is the most common cause of DEP. Since there are two main types of pancreatitis – acute pancreatitis and chronic pancreatitis, two subtypes of PPDM can be distinguished – post-acute and post-chronic pancreatitis diabetes mellitus.
To understand the current state of the problem, a literature review has been conducted summarizing the latest data on epidemiology, pathogenesis, risk factors, long-term outcomes and approaches to hypoglycemic therapy of DEP.
Keywords:diabetes of the exocrine pancreas; acute pancreatitis; chronic pancreatitis
Funding. The study had no sponsor support.
Conflict of interest. The authors declare no conflict of interest.
Contribution. Thematic publications reviewing, approval of the manuscript for publication – Ametov A.S.; thematic publications reviewing, writing of the article – Pashkova E.Yu.; thematic publications reviewing, presentation of the article – Antsiferova D.M., Amikishieva K.A.
For citation: Ametov A.S., Pashkova E.Yu., Antsiferova D.M., Amikishieva K.A. Diabetes mellitus in the outcome of acute and chronic pancreatitis. The current state of the problem. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2024; 13 (1): 45–57. DOI: https://doi.org/10.33029/2304-9529-2024-13-1-45-57 (in Russian)
References
1. World Health Organization. Diabetes. 2023. URL: https://www.who.int/ru/news-room/fact-sheets/detail/diabetes
2. Hart P.A., Bellin M.D., Andersen D.K., et al. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Lancet Gastroenterol Hepatol. 2016; 1 (3): 226–37.
3. Kononenko I.V., Smirnova O.M., Mayorov A. Yu., Shestakova M.V. Classification of diabetes. World Health Organization 2019. What’s new? Sakharni diabet [Diabetes Mellitus]. 2020; 23(4): 329–39. DOI: https://doi.org/10.14341/DM12405 (in Russian)
4. Ewald N., Kaufmann C., Raspe A., et al. Prevalence of diabetes mellitus secondary to pancreatic diseases (type 3c). Diabetes Metab Res Rev. 2012; 28 (4): 338–42.
5. Woodmansey C., McGovern A.P., McCullough K.A., et al. Incidence, Demographics, and clinical characteristics of diabetes of the exocrine pancreas (Type 3c): A retrospective cohort study. Diabetes Care. 2017; 40 (11): 1486–93.
6. Petrov M.S., Yadav D. Global epidemiology and holistic prevention of pancreatitis. Nat Rev Gastroenterol Hepatol. 2019; 16 (3): 175–84.
7. Cho J., Petrov M.S. Pancreatitis, pancreatic cancer, and their metabolic sequelae: Projected burden to 2050. Clin Transl Gastroenterol. 2020; 11 (11): e00251.
8. Lee Y.K., Huang M.Y., Hsu C.Y., Su Y.C. Bidirectional relationship between diabetes and acute pancreatitis: A population-based cohort study in Taiwan. Medicine. 2016; 95 (2): e2448.
9. Shen H.N., Yang C.C., Chang Y.H., et al. Risk of diabetes mellitus after first-attack acute pancreatitis: A national population-based study. Am J Gastroenterol. 2015; 110 (12): 1698–706.
10. Bendor C.D., Bardugo A., Zucker I., et al. Childhood pancreatitis and risk for incident diabetes in adulthood. Diabetes Care. 2020; 43 (1): 145–51.
11. Pendharkar S.A., Mathew J., Petrov M.S. Age- and sex-specific prevalence of diabetes associated with diseases of the exocrine pancreas: A population-based study. Dig Liver Dis. 2017; 49 (5): 540–4.
12. Xiao A.Y., Tan M.L.Y., Wu L.M., et al. Global incidence and mortality of pancreatic diseases: a systematic review, meta-analysis, and meta-regression of population-based cohort studies. Lancet Gastroenterol Hepatol. 2016; 1 (1): 45–55.
13. Das S.L.M., Singh P.P., Phillips A.R.J., et al. Newly diagnosed diabetes mellitus after acute pancreatitis: a systematic review and meta-analysis. Gut. 2014; 63 (5): 818–31.
14. Zhu X., Liu D., Wei Q., et al. New-onset diabetes mellitus after chronic pancreatitis diagnosis: A systematic review and meta-analysis. Pancreas. 2019; 48 (7): 868–75.
15. Ammann R.W., Akovbiantz A., Largiader F., Schueler G. Course and outcome of chronic pancreatitis. Longitudinal study of a mixed medical-surgical series of 245 patients. Gastroenterology. 1984; 85 (5 Pt 1): 820–8.
16. Lankisch P.G., Löhr-Happe A., Otto J., Creutzfeldt W. Natural course in chronic pancreatitis. Pain, exocrine and endocrine pancreatic insufficiency and prognosis of the disease. Digestion. 1993; 54(3): 148–55.
17. Sankaran S.J., Xiao A.Y., Wu L.M., et al. Frequency of progression from acute to chronic pancreatitis and risk factors: a meta-analysis. Gastroenterology. 2015; 149 (6): 1490–500.e1.
18. Bharmal S.H., Cho J., Alarcon Ramos G.C., et al. Trajectories of glycaemia following acute pancreatitis: a prospective longitudinal cohort study with 24 months follow-up. J Gastroenterol. 2020; 55 (8): 775–88.
19. Singh R.G., Nguyen N.N., Cervantes A., et al. Serum lipid profile as a biomarker of intra-pancreatic fat deposition: A nested cross-sectional study. Nutr Metab Cardiovasc Dis. 2019; 29 (9): 956–64.
20. Ko J., Stuart C.E., Modesto A.E., et al. Chronic pancreatitis is characterized by elevated circulating periostin levels related to intra-pancreatic fat deposition. J Clin Med Res. 2020; 12 (9): 568–78.
21. Singh R.G., Nguyen N.N., DeSouza S.V., et al. Comprehensive analysis of body composition and insulin traits associated with intra-pancreatic fat deposition in healthy individuals and people with new-onset prediabetes/diabetes after acute pancreatitis. Diabetes Obes Metab. 2019; 21 (2): 417–23.
22. Singh R.G., Cervantes A., Kim J.U., et al. Intrapancreatic fat deposition and visceral fat volume are associated with the presence of diabetes after acute pancreatitis. Am J Physiol Gastrointest Liver Physiol. 2019; 316 (6): G806–15.
23. Ko J., Skudder-Hill L., Cho J., et al. The relationship between abdominal fat phenotypes and insulin resistance in non-obese individuals after acute pancreatitis. Nutrients. 2020; 12 (9): 1–14.
24. Cinti F., Mezza T., Cefalo C., et al. Intrapancreatic adipose tissue accumulation is associated to beta cell dedifferentiation in humans. Diabetologia. 2022; 65 (Suppl 1): S 218.
25. Ho T.W., Wu J.M., Kuo T.C., et al. Change of both endocrine and exocrine insufficiencies after acute pancreatitis in non-diabetic patients: A nationwide population-based study. Medicine. 2015; 94(27): e1123.
26. Cho J., Scragg R., Petrov M.S. The influence of cholecystectomy and recurrent biliary events on the risk of post-pancreatitis diabetes mellitus: a nationwide cohort study in patients with first attack of acute pancreatitis. HPB (Oxford). 2021; 23 (6): 937–44.
27. DeSouza S.V., Priya S., Cho J., et al. Pancreas shrinkage following recurrent acute pancreatitis: an MRI study. Eur Radiol. 2019; 29 (7): 3746–56.
28. DeSouza S.V., Singh R.G., Yoon H.D., et al. Pancreas volume in health and disease: A systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2018; 12 (8):757–66.
29. Schrader H., Menge B.A., Schneider S., et al. Reduced pancreatic volume and beta-cell area in patients with chronic pancreatitis. Gastroenterology. 2009;136 (2): 513–22.
30. Zsóri G., Illés D., Terzin V., et al. Exocrine pancreatic insufficiency in type 1 and type 2 diabetes mellitus: do we need to treat it? A systematic review. Pancreatology. 2018; 18 (5): 559–65.
31. Bharmal S.H., Pendharkar S.A., Singh R.G., et al. Relationship between circulating levels of pancreatic proteolytic enzymes and pancreatic hormones. Pancreatology. 2017; 17 (6): 876–83.
32. Esteghamat F., Broughton J.S., Smith E., et al. CELA2A mutations predispose to early-onset atherosclerosis and metabolic syndrome and affect plasma insulin and platelet activation. Nat Genet. 2019; 51 (8): 1233–43.
33. Ko J., Cho J., Petrov M.S. Low serum amylase, lipase, and trypsin as biomarkers of metabolic disorders: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2020; 159: 107974.
34. Cho J., Scragg R., Pandol S.J., Petrov M.S. Exocrine pancreatic dysfunction increases the risk of new-onset diabetes mellitus: Results of a nationwide cohort study. Clin Transl Sci. 2021; 14 (1): 170–8.
35. Petrov M.S. Metabolic trifecta after pancreatitis: exocrine pancreatic dysfunction, altered gut microbiota, and new-onset diabetes. Clin Transl Gastroenterol. 2019; 10 (10): e00086.
36. Pendharkar S.A., Mathew J., Zhao J., et al. Ethnic and geographic variations in the incidence of pancreatitis and post-pancreatitis diabetes mellitus in New Zealand: a nationwide population-based study. N Z Med J. 2017;130 (1450): 55–68.
37. Klöppel G., Maillet B. The morphological basis for the evolution of acute pancreatitis into chronic pancreatitis. Virchows Arch A Pathol Anat Histopathol. 1992; 420 (1): 1–4.
38. Petrov M.S. Diagnosis of endocrine disease: Post-pancreatitis diabetes mellitus: prime time for secondary disease. Eur J Endocrinol. 2021; 184 (4): R 137–49.
39. Petrov M.S. Panorama of mediators in postpancreatitis diabetes mellitus. Curr Opin Gastroenterol. 2020; 36 (5): 443–51.
40. Petrov M.S., Basina M. Diagnosis of endocrine disease: Diagnosing and classifying diabetes in diseases of the exocrine pancreas. Eur. J. Endocrinol. 2021; 184 (4): R 151–63.
41. Pendharkar S.A., Asrani V.M., Murphy R., et al. The role of gut-brain axis in regulating glucose metabolism after acute pancreatitis. Clin Transl Gastroenterol. 2017; 8 (1): e210.
42. Gillies N.A., Pendharkar S.A., Singh R.G., et al. Fasting levels of insulin and amylin after acute pancreatitis are associated with pro-inflammatory cytokines. Arch Physiol Biochem. 2017; 123 (4): 238–48.
43. Bharmal S.H., Pendharkar S.A., Singh R.G., et al. Associations between ketone bodies and fasting plasma glucose in individuals with post-pancreatitis prediabetes. Arch Physiol Biochem. 2020; 126 (4): 308–19.
44. Pendharkar S.A., Singh R.G., Bharmal S.H., et al. Pancreatic hormone responses to mixed meal test in new-onset prediabetes/diabetes after non-necrotizing acute pancreatitis. J Clin Gastroenterol. 2020; 54 (2): e11–e20.
45. Bharmal S.H., Cho J., Stuart C.E., et al. Oxyntomodulin may distinguish new-onset diabetes after acute pancreatitis from type 2 diabetes. Clin Transl Gastroenterol. 2020; 11 (2): e00132.
46. Akalestou E., Christakis I., Solomou A.M., et al. Proglucagon-derived peptides do not significantly affect acute exocrine pancreas in rats. Pancreas. 2016; 45 (7): 967–73.
47. Shivaprasad C., Aiswarya Y., Kejal S., et al. Comparison of CGM-derived measures of glycemic variability between pancreatogenic diabetes and type 2 diabetes mellitus. J Diabetes Sci Technol. 2021; 15 (1): 134–40.
48. Cho J., Scragg R., Petrov M.S. Risk of mortality and hospitalization after post-pancreatitis diabetes mellitus vs type 2 diabetes mellitus: A population-based matched cohort study. Am J Gastroenterol. 2019; 114 (5): 804–12.
49. Cho J., Dalbeth N., Petrov M.S. Relationship between gout and diabetes mellitus after acute pancreatitis: A nationwide cohort study. J Rheumatol. 2020; 47 (6): 917–23.
50. Cho J., Scragg R., Petrov M.S. Postpancreatitis diabetes confers higher risk for pancreatic cancer than type 2 diabetes: Results from a nationwide cancer registry. Diabetes Care. 2020; 43 (9): 2106–12.
51. Cho J., Scragg R., Pandol S.J., et al. Antidiabetic medications and mortality risk in individuals with pancreatic cancer-related diabetes and postpancreatitis diabetes: A nationwide cohort study. Diabetes Care. 2019; 42 (9): 1675–83.
52. American Diabetes Association. 8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018; 41 (Suppl 1): S 73–85.
53. Erpeldinger S., Rehman M.B., Berkhout C., et al. Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials. BMC Endocr Disord. 2016; 16 (1): 39.
54. Cho J., Scragg R., Petrov M.S. Use of insulin and the risk of progression of pancreatitis: A population-based cohort study. Clin Pharmacol Ther. 2020; 107 (3): 580–7.
55. Colmers I.N., Bowker S.L., Tjosvold L.A., Johnson J.A. Insulin use and cancer risk in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies. Diabetes Metab. 2012; 38 (6): 485–506.
56. Kirkegård J., Mortensen F.V., Cronin-Fenton D. Chronic pancreatitis and pancreatic cancer risk: A systematic review and meta-analysis. Am J Gastroenterol. 2017; 112 (9): 1366–72.
57. Ballmann M., Hubert D., Assael B.M., et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018; 6 (2): 114–21.